Clinical Validation of AI-based Interpretation of PD-L1 Tumor Proportion Score in Predicting Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer In the field of tumor treatment and diagnosis, the assessment of PD-L1 (Programmed Death-Ligand 1) Tumor Proportion Score (TPS) is a critical task, especially in predicting the response ...

Tumor Cell-Intrinsic PD-L1 Signaling Induces Epithelial-Mesenchymal Transition (EMT) Predicting Poor Response to Immune Checkpoint Inhibitors in PD-L1 High-Expressing Lung Cancer Research Background and Motivation In cancer immunotherapy, Programmed Death Ligand-1 (PD-L1) inhibits immune responses by binding to Programmed Death-1 (PD-1) receptors o...

The research team consisting of Guilan Shi, Jody Synowiec, Julie Singh, and Richard Heller published a paper titled “Modification of the tumor microenvironment enhances immunity with plasmid gene therapy” in Cancer Gene Therapy. The background of the study stems from current challenges in the field of tumor immunotherapy, such as tumor cells evadin...

Acetate Reprograms Tumor Metabolism and Promotes Immune Evasion and PD-L1 Expression by Upregulating c-myc Introduction Reprogramming of tumor metabolism is of great significance in cancer research, and acetate plays a crucial role in this process. In tumor cells, acetate is an important precursor of acetyl-CoA, which is used for energy production,...